Appeal type: unknown
Decision: unknown

The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
The rules say that continuous glucose monitor (CGM) devices covered by Medicare under the DME benefit are 
defined in CMS Ruling 1682R as therapeutic CGMs. Refer to the Non-Medical Necessity Coverage and 
Payment Rules in the LCD-related Policy Article for additional information. Therapeutic CGMs and related 
supplies are covered by Medicare when all of the following coverage criteria (1-6) are met: 
  
1. The beneficiary has diabetes mellitus (Refer to the ICD-10 code list in the LCD-related Policy Article for 
applicable diagnoses); and, 
2. The beneficiary has been using a BGM and performing frequent (four or more times a day) testing; and, 
3. The beneficiary is insulin-treated with multiple (three or more) daily injections of insulin or a Medicare-
covered continuous subcutaneous insulin infusion (CSII) pump; and, 
4. The beneficiary's insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of 
BGM or CGM testing results; and, 
5. Within six (6) months prior to ordering the CGM, the treating practitioner has an in-person visit with the 
beneficiary to evaluate their diabetes control and determined that criteria (1-4) above are met; and, 
6. Every six (6) months following the initial prescription of the CGM, the treating practitioner has an in-person 
visit with the beneficiary to assess adherence to their CGM regimen and diabetes treatment plan. 
  
You can find this rule in Local Coverage Determination (LCD): Glucose Monitors (L33822) - Effective 
January 1, 2020. 
  
The rules say that continuous glucose monitors (CGMs) are class III medical devices, and require premarket 
approval by the Food and Drug Administration (FDA). For the purpose of this Ruling, all CGMs that are 
approved by the FDA for use as adjunctive devices to complement, not replace, information obtained from 
blood glucose monitors in making diabetes treatment decisions are referred to as "non-therapeutic" CGMs. 
According to the FDA approval letter for the therapeutic CGM: the indications for use of the product have been 
expanded to include replacement of blood glucose monitors for diabetes treatment decisions; the device is 
indicated as a glucose monitoring system for the management of diabetes in persons age 2 years and older; 
interpretation of the results of the device should be based on the glucose trends and several sequential readings 
over time; the product also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating 
both acute and long-term therapy adjustments; and the device is intended for single patient use and requires a 
prescription.  The therapeutic CGM must be calibrated twice a day using a blood glucose monitor. Based on 
this information, the therapeutic CGM is designed and approved to replace a blood glucose monitor currently 
classified as DME under the Medicare program, but the device must be calibrated twice a day using a blood 
glucose monitor. You can find this rule in CMS Ruling 1682R. 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com. 
 
The Plan contract says that the Plan covers items and services in accordance with Medicare rules.